Role of fenofibrate in restoring angiogenesis in diabetic and control hind limb ischemic rats

General Physiology and Biophysics

Volumn 31, Issue 3, 2012, Pages 255-260

  Salehi, Ensieh ^a   Khazaei, Majid ^a   Rashidi, Bahman ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiogenesis; Diabetes; Fenofibrate; Hind limb ischemia; Nitric oxide

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; NITRITE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CAPILLARY DENSITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; HIND LIMB ISCHEMIA; IMMUNOHISTOCHEMISTRY; LIMB ISCHEMIA; MALE; NONHUMAN; RAT;

ANIMALS; DIABETIC ANGIOPATHIES; FENOFIBRATE; HINDLIMB; HYPOLIPIDEMIC AGENTS; ISCHEMIA; MALE; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE; PPAR GAMMA; RATS; RATS, WISTAR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84867787793     PISSN: 02315882     EISSN: 13384325     Source Type: Journal    
DOI: 10.4149/gpb-2012-033     Document Type: Article

References (23)

1. Biscetti F., Gaetani E., Flex A., Aprahamian T., Hopkins T., Straface G., Pecorini G., Stigliano E., Smith R. C., Angelini F., Castellot J. J., Jr., Pola R. (2008): Selective activation of peroxisome proliferator-activated receptor (PPAR) alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 57, 1394-1404 http://dx.doi.org/10.2337/db07-0765
2. Biscetti F., Straface G., Pitocco D., Zaccardi F., Ghirlanda G., Flex A. (2009): Peroxisome proliferator-activated receptors and angiogenesis. Nutr. Metab Cardiovasc. Dis. 19, 751-759 http://dx.doi.org/10.1016/j.numecd.2009.04. 011
3. Calkin A. C., Thomas M. C. (2008): PPAR agonists and cardiovascular disease in diabetes. PPAR Res. 2008, 245410 http://dx.doi.org/10.1155/2008/ 245410 (Pubitemid 351171867)
4. Cooke J. P., Losordo D. W. (2002): Nitric oxide and angiogenesis. Circulation 105, 2133-2135 http://dx.doi.org/10.1161/01. CIR.0000014928.45119.73 (Pubitemid 34517153)
5. Evans M., Anderson R. A., Graham J., Ellis G. R., Morris K., Davies S., Jackson S. K., Lewis M. J., Frenneaux M. P., Rees A. (2000): Ciprofibrate therapy improvesendothelialfunction and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 101, 1773-1779 http://dx.doi.org/10.1161/01. CIR.101.15.1773 (Pubitemid 30213097)
6. Forcheron F., Cachefo A., Thevenon S., Pinteur C., Beylot M. (2002): Mechanisms of the triglyceride-and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes 51, 3486-3491 http://dx.doi.org/10.2337/diabetes.51.12.3486 (Pubitemid 35403454)
7. Fukumura D., Gohongi T., Kadambi A., Izumi Y., Ang J., Yun C. O., Buerk D. G., Huang P. L., Jain R. K. (2001): Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl. Acad. Sci. U. S. A. 98, 2604-2609 http://dx.doi.org/10.1073/pnas.041359198 (Pubitemid 32209529)
8. Gaede P., Vedel P., Larsen N., Jensen G. V., Parving H. H., Pedersen O. (2003): Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348, 383-393 http://dx.doi.org/10.1056/ NEJMoa021778 (Pubitemid 36159355)
9. Guo Q., Wang P. R., Milot D. P., Ippolito M. C., Hernandez M., Burton C. A., Wright S. D., Chao Y. (2001): Regulation of lipid metabolism and gene expression by fenofibrate in hamsters. Biochim. Biophys. Acta 1533, 220-232 (Pubitemid 33127273)
10. Huang P. H., Sata M., Nishimatsu H., Sumi M., Hirata Y., Nagai R. (2008): Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed. Pharmacother. 62, 46-52 http://dx.doi.org/10.1016/j.biopha.2007.06.014
11. Issemann I., Green S. (1990): Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645-650 http://dx.doi.org/10.1038/347645a0 (Pubitemid 20356241)
12. Karamysheva A. F. (2008): Mechanisms of angiogenesis. Biochemistry (Mosc.) 73, 751-762 http://dx.doi.org/10.1134/S0006297908070031
13. Katayama A., Yamamoto Y., Tanaka K., Matsubara K., Sugitani M., Fujihara S., Harada S., Kaetsu Y., Yoshida A., Hisatome I. (2009): Fenofibrate enhances neovascularization in a murine ischemic hind limb model. J. Cardiovasc. Pharmacol. 54, 399-404 http://dx.doi.org/10.1097/FJC.0b013e3181bad05d
14. Lloyd P. G., Yang H. T., Terjung R. L. (2001): Arteriogenesis and angiogenesis in rat ischemic hind limb: role of nitric oxide. Am. J. Physiol. Heart Circ. Physiol. 281, H2528-2538
15. Luque C. D., Vargas R. H., Romo E., Rios A., Escalante B. (2006): The role of nitric oxide in the post-ischemic revascularization process. Pharmacol. Ther. 112, 553-563 http://dx.doi.org/10.1016/j.pharmthera.2006.05.003 (Pubitemid 44486414)
16. Martin A., Komada M. R., Sane D. C. (2003): Abnormal angiogenesis in diabetes mellitus. Med. Res. Rev. 23, 117-145 http://dx.doi.org/10.1002/med. 10024 (Pubitemid 36241095)
17. Namba T., Koike H., Murakami K., Aoki M., Makino H., Hashiya N., Ogihara T., Kaneda Y., Kohno M., Morishita R. (2003): Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hind limb ischemia model. Circulation 108, 2250-2257 http://dx.doi.org/10.1161/01. CIR.0000093190.53478.78 (Pubitemid 37363043)
18. Panigrahy D., Kaipainen A., Huang S., Butterfield C. E., Barnes C. M., Fannon M., Laforme A. M., Chaponis D. M., Folkman J., Kieran M. W. (2008): PPARalpha agonist fenofibratesuppresses tumor growth through direct and indirect angiogenesis inhibition. Proc. Natl. Acad. Sci. U. S. A. 105, 985-990 http://dx.doi.org/10.1073/pnas.0711281105 (Pubitemid 351282068)
19. Playford D. A., Watts G. F., Best J. D., Burke V. (2002): Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus. Am. J. Cardiol. 90, 1254-1257 http://dx.doi.org/10.1016/S0002-9149 (02) 02847-3 (Pubitemid 35346887)
20. Taniyama Y., Morishita R., Aoki M., Nakagami H., Yamamoto K., Yamazaki K., Matsumoto K., Nakamura T., Kaneda Y., Ogihara T. (2001): Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hind limb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther. 8, 181-189 http://dx.doi.org/10.1038/sj.gt.3301379 (Pubitemid 32186129)
21. Touyz R. M., Schiffrin E. L. (2006): Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Vascul. Pharmacol. 45, 19-28 http://dx.doi.org/10.1016/j.vph.2005.11.014 (Pubitemid 43963482)
22. Varet J., Vincent L., Mirshahi P., Pille J. V., Legrand E., Opolon P., Mishal Z., Soria J., Li H., Soria C. (2003): Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell. Mol. Life Sci. 60, 810-819 http://dx.doi.org/10. 1007/s00018-003-2322-6 (Pubitemid 36570772)
23. Waltenberger J. (2001): Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc. Res. 49, 554-560 http://dx.doi.org/10.1016/S0008-6363 (00) 00228-5 (Pubitemid 32146418)